Ann: Imugene Appoints Kim Drapkin as Non-Executive Director, page-2

Kim Drapkin brings more than 20 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Ms. Drapkin has worked with Jounce since its inception, playing a key role in building Jounce’s financial infrastructure, and came into the role with an already deep understanding of Jounce’s strategy and culture. Prior to joining Jounce, Ms. Drapkin owned a financial consulting firm where she served as the interim chief financial officer for numerous early-stage biotechnology companies, including Jounce, Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals and Voyager Therapeutics, Inc. Previously, Ms. Drapkin was chief financial officer at EPIX Pharmaceuticals. Prior to EPIX, Ms. Drapkin spent ten years in roles of increasing responsibility within the finance organization at Millennium Pharmaceuticals. Ms. Drapkin began her career in the technology and life sciences practice at PriceWaterhouseCoopers LLP. Ms. Drapkin received her B.S. in accounting from Babson College